methyl 2-chloro-5-[[7-[[N-[7-[(4-chloro-3-methoxycarbonylphenyl)sulfamoyl]naphthalen-2-yl]-C-methylsulfanylcarbonimidoyl]amino]naphthalen-2-yl]sulfonylamino]benzoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: methyl 2-chloro-5-[[7-[[N-[7-[(4-chloro-3-methoxycarbonylphenyl)sulfamoyl]naphthalen-2-yl]-C-methylsulfanylcarbonimidoyl]amino]naphthalen-2-yl]sulfonylamino]benzoate
• 化学式: C₃₈H₃₀Cl₂N₄O₈S₃
• 分子量: 837.8
• InChiKey: AABFMMVSPCTKNP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.4
• 重原子数：
  55
• 可旋转键数：
  14
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  211
• 氢给体数：
  3
• 氢受体数：
  12

文献信息

• Novel naphthalene ureas as glucose uptake enhancers
  申请人：——

  公开号：US20030135063A1

  公开（公告）日：2003-07-17

  Compounds of formula I are useful for treating conditions associated with hyperglycemia, especially Type II diabetes. These compounds are useful in stimulating the kinase activity of the insulin receptor, activating the insulin receptor, and stimulating the uptake of glucose. Pharmaceutical compositions comprising the antidiabetic compounds are also disclosed.

  公式I的化合物对于治疗与高血糖有关的疾病，特别是2型糖尿病非常有用。这些化合物在刺激胰岛素受体的激酶活性、激活胰岛素受体和促进葡萄糖的摄取方面非常有用。还公开了包含抗糖尿病化合物的药物组合物。
• NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS
  申请人：Telik, Inc.

  公开号：EP1181271A2

  公开（公告）日：2002-02-27
• US6458998B1
  申请人：——

  公开号：US6458998B1

  公开（公告）日：2002-10-01
• US7071231B2
  申请人：——

  公开号：US7071231B2

  公开（公告）日：2006-07-04
• [EN] NOVEL NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS<br/>[FR] NOUVELLES NAPHTALENE UREES UTILES EN TANT QU'ACTIVATEURS DE L'ABSORPTION DU GLUCOSE
  申请人：TELIK INC

  公开号：WO2000071506A2

  公开（公告）日：2000-11-30

  Compounds of formula (I), wherein R?1 and R2¿ are substituents on the A rings and are, independently, -SO¿2NR?72, -C(O)NR72, -NR7SO2R?7, -NR7C(O)R7, -SO¿2OR7, -C(O)OR7, -OSO¿2R?7, or -OC(O)R?7, R3 and R4¿ are, independently, hydrogen or lower alkyl, or R?3 and R4¿ together are -(CH¿2?)2-, -(CH2)3-, or -(CH2)4-, or R?3 or R4¿ may be an electron pair, R?5 and R6¿ are, independently, hydrogen, alkyl, substituted alkyl, cyano, halo, nitro, -SR8, -C(O)R8, -SO2OR8, -OSO¿2?R?8, -SO¿2NR82, -NR8SO2R8, -OC(O)R8, -C(O)OR8, -C(O)NR82, -NR?8C(O)R8, -OR8¿, or -NR82, each R?7 and R8¿ is, independently, hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aryl(lower)alkyl, substituted aryl(lower)alkyl, heteroaryl(lower)alkyl, substituted heteroaryl(lower)alkyl, heterocyclyl, substituted heterocyclyl, heteroaryl, or substituted heteroaryl, each Y is, independently, a non-interfering substituent which is not linked to the naphthalene ring via an azo or amide linkage, each x is independently, 0, 1 or 2, and the linker connects a carbon designated as c to a carbon designated as d, or a pharmaceutically acceptable salt thereof, as a single stereoisomer or mixture of stereoisomers, are useful for treating conditions associated with hyperglycemia, especially Type II diabetes, with dinaphthylureas. These compounds are useful in stimulating the kinase activity of the insulin receptor, activating the insulin receptor, and stimulating the uptake of glucose. Pharmaceutical compositions comprising the antidiabetic compounds are also disclosed.